Orient Pharma Co., Ltd. (TPEX:4166)

Market Cap	6.08B -28.6%
Revenue (ttm)	1.41B +11.9%
Net Income	196.58M +63.9%
EPS	0.83 +55.3%
Shares Out	223.04M
PE Ratio	32.64
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	459,954
Open	27.90
Previous Close	27.20
Day's Range	27.15 - 27.90
52-Week Range	22.30 - 37.70
Beta	0.09
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Orient Pharma

Orient Pharma Co., Ltd. engages in the development of new drugs in Taiwan and internationally. It offers cardiovascular drugs, such as Pitator and Tonvasca for lipid suppression, as well as Zulitor, a lipid lowering drug; psychotropic drugs, including Trokendi XR extended, Methydur, and powder and solvent for prolonged-release suspension for injection. The company was founded in 2008 and is based in Taipei, Taiwan.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2008
• Employees: 173
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4166

Financial Performance

In 2025, Orient Pharma's revenue was 1.40 billion, an increase of 14.52% compared to the previous year's 1.22 billion. Earnings were 208.44 million, an increase of 94.12%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 9, 2026

Data Sources Report a data error